As Chen et al. suggested, METTL3-mediated NIFK-AS1 down-regulation functions to increase the uptake of sorafenib, thereby enhancing sorafenib resistance of HCC (Chen et al., 2021b). This evidence concerns the gene METTL3 and hepatocellular carcinoma.